Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nadja M Meindl-Beinker

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cells|October 15, 2024
Role of WISP1 in Stellate Cell Migration and Liver FibrosisDaniela González, Gisela Campos, Larissa Pütter, et al.
Journal of Geriatric Oncology|August 3, 2024
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA studyMoying Li, Nadja M Meindl-Beinker, Martin Maenz, et al.
The Lancet. Healthy Longevity|September 13, 2022
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trialMatthias P Ebert, Nadja M Meindl-Beinker, Tobias Gutting, et al.
Clinical Science (London, England : 1979)|January 21, 2015
Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinomaTeng Feng, Johanna Dzieran, Xing Gu, et al.
Science Immunology|May 3, 2024
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillanceMichael Kilian, Mirco J Friedrich, Kevin Hai-Ning Lu, et al.
Alcoholism, Clinical and Experimental Research|October 29, 2009
Alcohol, signaling, and ECM turnoverDevanshi Seth, Nympha B D'Souza El-Guindy, Minoti Apte, et al.
Biochemical and Biophysical Research Communications|July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effectsAnne Dropmann, Sophie Alex, Katharina Schorn, et al.
Gut|January 30, 2020
TGF-β2 silencing to target biliary-derived liver diseasesAnne Dropmann, Steven Dooley, Bedair Dewidar, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cells|October 15, 2024
Role of WISP1 in Stellate Cell Migration and Liver FibrosisDaniela González, Gisela Campos, Larissa Pütter, et al.
Journal of Geriatric Oncology|August 3, 2024
Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA studyMoying Li, Nadja M Meindl-Beinker, Martin Maenz, et al.
The Lancet. Healthy Longevity|September 13, 2022
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trialMatthias P Ebert, Nadja M Meindl-Beinker, Tobias Gutting, et al.
Clinical Science (London, England : 1979)|January 21, 2015
Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinomaTeng Feng, Johanna Dzieran, Xing Gu, et al.
Science Immunology|May 3, 2024
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillanceMichael Kilian, Mirco J Friedrich, Kevin Hai-Ning Lu, et al.
Alcoholism, Clinical and Experimental Research|October 29, 2009
Alcohol, signaling, and ECM turnoverDevanshi Seth, Nympha B D'Souza El-Guindy, Minoti Apte, et al.
Biochemical and Biophysical Research Communications|July 21, 2024
The TGF-β1 target WISP1 is highly expressed in liver cirrhosis and cirrhotic HCC microenvironment and involved in pro- and anti-tumorigenic effectsAnne Dropmann, Sophie Alex, Katharina Schorn, et al.
Gut|January 30, 2020
TGF-β2 silencing to target biliary-derived liver diseasesAnne Dropmann, Steven Dooley, Bedair Dewidar, et al.
Pageof 3